Stock Events

Stock Events

Antisense Therapeutics Limited 

$0.06
7
+$0+0% Friday 20:00

Statistics

Day High
0.05
Day Low
0.05
52W High
0.08
52W Low
0.01
Volume
17,272
Avg. Volume
390
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jul 21
$0.09
Nov 20
$0.04
Jul 20
$0.07
Nov 19
$0.03
Jul 19
$0.06
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

26FebExpected
Q2 2024
Q4 2024
Q2 2025
Q4 2025
-0.01
-0.01
-0
-0
Expected EPS
N/A
Actual EPS
-0.00188498125

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-8.02MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ATHJF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a key competitor in the cystic fibrosis market, directly competing with Percheron Therapeutics' treatments in this area.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes in multiple therapeutic areas including immunology and oncology, overlapping with Percheron's research and drug development efforts.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is involved in biopharmaceuticals targeting genetic disorders, directly competing with Percheron's gene therapy projects.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics in areas like oncology and cardiovascular disease, which are also interest areas for Percheron Therapeutics.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences operates in the field of antiviral drugs, including treatments for HIV, hepatitis B, hepatitis C, and influenza, competing with Percheron's antiviral programs.
Biogen
BIIB
Mkt Cap22.63B
Biogen's focus on neurological diseases and innovative therapies places it in direct competition with Percheron's neurological drug development.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical targets rare genetic diseases, a field where Percheron is also actively developing treatments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals works on RNAi therapeutics, competing with Percheron's similar efforts in gene silencing technologies.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments in areas where Percheron Therapeutics is also active, such as cardiovascular, oncology, and neurology.

About

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.
Show more...
CEO
Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA
Country
US

Listings

AU
AU
PER.AU
F
DE
AWY0.F
OTC Link
US
PERCF

0 Comments

Share your thoughts

FAQ

What is Antisense Therapeutics Limited stock price today?▼
The current price of ATHJF is $0.06 USD — it has increased by +0% in the past 24 hours. Watch Antisense Therapeutics Limited stock price performance more closely on the chart.
What is Antisense Therapeutics Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Antisense Therapeutics Limited stocks are traded under the ticker ATHJF.
What is Antisense Therapeutics Limited revenue for the last year?▼
Antisense Therapeutics Limited revenue for the last year amounts to 0 USD.
What is Antisense Therapeutics Limited net income for the last year?▼
ATHJF net income for the last year is -8.02M USD.
In which sector is Antisense Therapeutics Limited located?▼
Antisense Therapeutics Limited operates in the Health Care sector.
When did Antisense Therapeutics Limited complete a stock split?▼
Antisense Therapeutics Limited has not had any recent stock splits.
Where is Antisense Therapeutics Limited headquartered?▼
Antisense Therapeutics Limited is headquartered in Melbourne, US.